CEPHEUS Trial: Efficacy in Transplant-Ineligible Patients
June 23rd 2025Panelists discuss updated American Society of Clinical Oncology (ASCO) data showing that 4-drug regimens significantly improve outcomes even in patients with transplant-ineligible multiple myeloma, with real-world dose modifications enabling broader use while maintaining efficacy and tolerability.
CEPHEUS Trial: Design/Baseline Characteristics
June 16th 2025Panelists discuss how recent data support the use of quadruplet regimens—including anti-CD38 antibodies—even in older or moderately frail patients with newly diagnosed multiple myeloma, shifting treatment decisions from transplant eligibility to functional status and depth of response.
Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
June 16th 2025Panelists discuss how subcutaneous anti-CD38 monoclonal antibodies are reshaping frontline multiple myeloma treatment by improving efficacy, tolerability, and patient convenience across both transplant-eligible and ineligible populations.